慢性阿司匹林治疗期间水杨酸盐的代谢
Metabolism of salicylate during chronic aspirin therapy.
作者信息
Rumble R H, Brooks P M, Roberts M S
出版信息
Br J Clin Pharmacol. 1980 Jan;9(1):41-5. doi: 10.1111/j.1365-2125.1980.tb04794.x.
Abstract
- The effects of chronic administration of aspirin in therapeutic doses (3.9 g/day) on plasma and salivary salicylate levels were studied in eight subjects. 2. The urinary excretion profile for free salicylic acid and metabolites of salicylate were examined. 3. Plasma and salivary salicylate levels declined significantly after peak levels were achieved between days 3 and 10. 4. The decline in plasma and salivary salicylate levels may be due to an induction of a metabolic pathway such as salicylurate formation (Furst, Gupta & Paulus, 1977). Only the mean fraction of salicylate excreted as salicylurate appears to increase with time during the present study, although the change was not significant statistically. 5. The decline in plasma and salivary salicylate levels during chronic therapy may lead to an apparent 'tolerance' of some rheumatoid patients to aspirin.
摘要
- 研究了八名受试者长期服用治疗剂量的阿司匹林（3.9克/天）对血浆和唾液中水杨酸盐水平的影响。2. 检测了游离水杨酸和水杨酸盐代谢产物的尿排泄情况。3. 在第3天至第10天达到峰值水平后，血浆和唾液中的水杨酸盐水平显著下降。4. 血浆和唾液中水杨酸盐水平的下降可能是由于诱导了一种代谢途径，如水杨尿酸的形成（Furst、Gupta和Paulus，1977年）。在本研究中，只有作为水杨尿酸排泄的水杨酸盐平均比例似乎随时间增加，尽管这一变化在统计学上并不显著。5. 长期治疗期间血浆和唾液中水杨酸盐水平的下降可能导致一些类风湿性关节炎患者对阿司匹林产生明显的“耐受性”。
相似文献
1
Metabolism of salicylate during chronic aspirin therapy.慢性阿司匹林治疗期间水杨酸盐的代谢
Br J Clin Pharmacol. 1980 Jan;9(1):41-5. doi: 10.1111/j.1365-2125.1980.tb04794.x.
2
Correlation of plateau serum salicylate level with rate of salicylate metabolism.
Clin Pharmacol Ther. 1975 Sep;18(3):350-5. doi: 10.1002/cpt1975183350.
3
Fetal acquisition and neonatal elimination of a large amount of salicylate. Study of a neonate whose mother regularly took therapeutic doses of aspirin during pregnancy.
Clin Pharmacol Ther. 1975 Jan;17(1):98-103. doi: 10.1002/cpt197517198.
4
Comparative plasma salicylate and urine salicylurate levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate.
J Pharm Sci. 1980 Nov;69(11):1355-6. doi: 10.1002/jps.2600691133.
5
Availability of salicylate from salsalate and aspirin.
Clin Pharmacol Ther. 1983 Oct;34(4):539-45. doi: 10.1038/clpt.1983.211.
6
Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.
Eur J Clin Pharmacol. 1987;32(2):153-8. doi: 10.1007/BF00542188.
7
Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis.
Clin Pharmacol Ther. 1977 Oct;22(4):410-20. doi: 10.1002/cpt1977224410.
8
Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formation.双胞胎中的水杨酸盐代谢。表明存在遗传影响及诱导水杨尿酸盐形成的证据。
J Clin Invest. 1977 Jul;60(1):32-42. doi: 10.1172/JCI108766.
9
Kinetics of salicylate metabolism.水杨酸盐代谢动力学。
Br J Clin Pharmacol. 1975 Jun;2(3):233-8. doi: 10.1111/j.1365-2125.1975.tb01581.x.
10
Clinical pharmacokinetics of the salicylates.水杨酸盐类的临床药代动力学
Clin Pharmacokinet. 1985 Mar-Apr;10(2):164-77. doi: 10.2165/00003088-198510020-00004.
引用本文的文献
1
P2RY12-Inhibitors Reduce Cancer-Associated Thrombosis and Tumor Growth in Pancreatic Cancers.P2RY12抑制剂可减少胰腺癌中的癌症相关血栓形成和肿瘤生长。
Front Oncol. 2021 Sep 13;11:704945. doi: 10.3389/fonc.2021.704945. eCollection 2021.
2
Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis.小剂量阿司匹林和硫酸镁治疗妊娠期高血压疾病的疗效与安全性：一项系统评价和荟萃分析方案
Medicine (Baltimore). 2020 Nov 13;99(46):e22801. doi: 10.1097/MD.0000000000022801.
3
Correlation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT.长期服用阿司匹林与通过PET/CT测量的结直肠癌中F-氟脱氧葡萄糖摄取之间的相关性。
PLoS One. 2014 Oct 7;9(10):e109459. doi: 10.1371/journal.pone.0109459. eCollection 2014.
4
Drug structure-transport relationships.药物结构-转运关系。
J Pharmacokinet Pharmacodyn. 2010 Dec;37(6):541-73. doi: 10.1007/s10928-010-9174-0. Epub 2010 Nov 24.
5
Monitoring plasma concentrations of salicylate.监测水杨酸盐的血浆浓度。
Clin Pharmacokinet. 1980 Sep-Oct;5(5):424-40. doi: 10.2165/00003088-198005050-00002.
6
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates.水杨酸酯治疗的类风湿关节炎患者中水杨尿酸形成的诱导。
Clin Pharmacokinet. 1983 May-Jun;8(3):263-71. doi: 10.2165/00003088-198308030-00005.
7
Clinical pharmacokinetics of the salicylates.水杨酸盐类的临床药代动力学
Clin Pharmacokinet. 1985 Mar-Apr;10(2):164-77. doi: 10.2165/00003088-198510020-00004.
8
The effect of concurrent aspirin upon plasma concentrations of tenoxicam.同时服用阿司匹林对替诺昔康血浆浓度的影响。
Br J Clin Pharmacol. 1988 Oct;26(4):455-62. doi: 10.1111/j.1365-2125.1988.tb03405.x.
9
Salicylate pharmacokinetics in patients with rheumatoid arthritis.类风湿性关节炎患者的水杨酸盐药代动力学。
Br J Clin Pharmacol. 1989 Oct;28(4):449-61. doi: 10.1111/j.1365-2125.1989.tb03526.x.
10
Adverse reactions and interactions with aspirin. Considerations in the treatment of the elderly patient.阿司匹林的不良反应及相互作用。老年患者治疗中的注意事项。
Drug Saf. 1990 Sep-Oct;5(5):317-27. doi: 10.2165/00002018-199005050-00002.
本文引用的文献
1
Determination of acetylsalicylic acid and salicylic acid in plasma.血浆中乙酰水杨酸和水杨酸的测定。
J Pharm Sci. 1967 Jun;56(6):717-20. doi: 10.1002/jps.2600560611.
2
Capacity-limited salicylurate formation during prolonged administration of aspirin to healthy human subjects.
J Pharm Sci. 1969 Apr;58(4):503-4. doi: 10.1002/jps.2600580432.
3
Drug biotransformation interactions in man. I. Mutual inhibition in glucuronide formation of salicylic acid and salicylamide in man.人体中的药物生物转化相互作用。I. 人体中水杨酸和水杨酰胺葡萄糖醛酸苷形成的相互抑制作用。
J Pharm Sci. 1968 Aug;57(8):1330-5. doi: 10.1002/jps.2600570811.
4
Variations of serum concentrations and half-life of salicylate in patients with rheumatoid arthritis.
Arthritis Rheum. 1971 Jul-Aug;14(4):527-32. doi: 10.1002/art.1780140412.
5
Application of salivary salicylate data to biopharmaceutical studies of salicylates.唾液水杨酸数据在水杨酸盐生物制药研究中的应用。
J Pharm Sci. 1972 Aug;61(8):1219-22. doi: 10.1002/jps.2600610810.
6
Salicylate accumulation kinetics in man.人体中水杨酸盐的蓄积动力学
N Engl J Med. 1972 Aug 31;287(9):430-2. doi: 10.1056/NEJM197208312870903.
7
Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man.
Clin Pharmacol Ther. 1972 Mar-Apr;13(2):258-68. doi: 10.1002/cpt1972132258.
8
Pharmacokinetics of tolbutamide: prediction by concentration in saliva.甲苯磺丁脲的药代动力学：通过唾液浓度进行预测。
Clin Pharmacol Ther. 1974 Dec;16(6):1052-8. doi: 10.1002/cpt19741661052.
9
Relationship between dose and apparent volume of distribution of salicylate in children.儿童水杨酸盐剂量与表观分布容积之间的关系。
Pediatrics. 1974 Dec;54(6):713-7.
10
Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis.
Clin Pharmacol Ther. 1977 Oct;22(4):410-20. doi: 10.1002/cpt1977224410.
Zotero 插件